Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033

Back to Search
Print
Bookmark Trial

NCT00376285

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- BMI of 30-40 kg/m2

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Women of childbearing potential

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

ObesitySafety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
NCT00331175
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityA 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
NCT00391196
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Huntsville, Alabama
  4. Mobile, Alabama
  5. Chandler, Arizona
  6. Mesa, Arizona
  7. Phoenix, Arizona
  8. Fresno, California
  9. Palm Springs, California
  10. Tustin, California
  11. Walnut Creek, California
  12. New Britain, Connecticut
  13. Washington, District of Columbia
  14. Orlando, Florida
  15. West Palm Beach, Florida
  16. Honolulu, Hawaii
  17. Gurnee, Illinois
  18. Madisonville, Kentucky
  19. Baton Rouge, Louisiana
  20. Metairie, Louisiana
  21. Auburn, Maine
  22. Scarborough, Maine
  23. Baltimore, Maryland
  24. Bay City, Michigan
  25. Troy, Michigan
  26. Edina, Minnesota
  27. Jefferson City, Missouri
  28. Albuquerque, New Mexico
  29. Buffalo, New York
  30. New York, New York
  31. Greenville, North Carolina
  32. Beaver, Pennsylvania
  33. Cumberland, Rhode Island
  34. Pawtucket, Rhode Island
  35. Greer, South Carolina
  36. Bristol, Tennessee
  37. Nashville, Tennessee
  38. Dallas, Texas
  39. Dallas, Texas
  40. San Antonio, Texas
  41. San Antonio, Texas
  42. Renton, Washington
  43. Morgantown, West Virginia
  44. Buenos Aires,
  45. Buenos Aires,
  46. Buenos Aires,
  47. Garran, Australian Capital Territory
  48. Wollongong, New South Wales
  49. Adelaide, South Australia
  50. Box Hill, Victoria
  51. Nedlands, Western Australia
  52. Curitiba, PR
  53. Porto Alegre, RS
  54. São Paulo, SP
  55. São Paulo, SP
  56. São Paulo, SP
  57. São Paulo, SP
  58. Red Deer, Alberta
  59. Coquitlam, British Columbia
  60. Winnipeg, Manitoba
  61. Thornhill, Ontario
  62. Charlottetown, Prince Edward Island
  63. L'Ancienne-Lorette, Quebec
  64. Saint-Marc-des-Carrières, Quebec
  65. Breclav,
  66. Ceske Budejovice,
  67. Olomouc,
  68. Praha 2,
  69. Praha 4 - Krc,
  70. Berlin,
  71. Dresden,
  72. Duesseldorf,
  73. Hamburg,
  74. Leipzig,
  75. Mittweida,
  76. Tampico, Cd. Madero
  77. Mexico, DF
  78. Guadalajara, Jalisco
  79. Monterrey, Nuevo León
  80. Banska Bystrica,
  81. Bratislava,
  82. Lubochna,
  83. Nitra,
  84. Goteborg,
  85. Huddinge,
  86. Edinburgh, Lothian
  87. Bath, Somerset
  88. Coventry,
  89. Dumfries,
  90. Dundee,
  91. Luton,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityA Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects
NCT01472848
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityStudy of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
NCT00471172
  1. Los Angeles, California
  2. Clearwater, Florida
  3. Kissimmee, Florida
  4. Pembroke Pines, Florida
  5. Lexington, Kentucky
  6. Louisville, Kentucky
  7. Milford, Massachusetts
  8. Charlotte, North Carolina
  9. Harleysville, Pennsylvania
  10. Warwick, Rhode Island
  11. Nashville, Tennessee
  12. Milwaukee, Wisconsin
ALL GENDERS
25 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
Official Title  ICMJE A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects
Brief Summary The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Condition  ICMJE Obesity
Intervention  ICMJE
  • Drug: CP-742,033
  • Drug: Fenofibrate
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: April 21, 2015)		0
Original Enrollment  ICMJE
 (submitted: September 13, 2006)		30
Study Completion Date  ICMJE Not Provided
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • BMI of 30-40 kg/m2

Exclusion Criteria:

  • Women of childbearing potential
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00376285
Other Study ID Numbers  ICMJE A5431015
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP